mHealth Alert: FCC Extends Boston Scientific's Authority for Implanted Cardiac Devices

The Federal Communications Commission (FCC) recently granted a rule waiver requested by Boston Scientific Corporation (Boston Scientific), allowing it to continue to manufacture and market its Contak Renewal TR product line of implanted cardiac medical devices. The rule waiver remains valid until May 8, 2011 or 90 days after the date on which the Food and Drug Administration (FDA) approves Boston Scientific’s replacement for the Contak Renewal TR devices (the Cognis CRT-P product line), whichever comes earlier.

Please see full alert for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Digital Health, FCC, FDA, Healthcare, Medical Devices, mHealth

Published In: Administrative Agency Updates, General Business Updates, Communications & Media Updates, Health Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Mintz Levin - Health Law & Policy Matters | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »